Bluejay Diagnostics, Inc.

BJDX

Healthcare Medical Devices

Bluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00.

EPS
+80.1%
Free cash flow
+20.1%

Quarter to June 2026, against a year earlier

2.35 0.16 +7.31%
Market cap
$2.6M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.8×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(126.19%) (117.02%) (171.56%) (98.89%)
ROA
(103.45%) (99.42%) (126.94%) (81.07%)
ROIC
(714.15%) (536.22%) (881.17%) 0.00%
Return on Tangible Assets
(190.40%) (116.49%) (169.10%) (77.83%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(15.37) (14.47) (6.75) (3.00)
Free Cash Flow
(6.05) (6.50) (6.65) (6.24)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026